search

Sign In / Join

search

close

person Sign In / Create Account

AML News

The HealthTree News for AML is a place to learn all about AML in easy-to-understand language. The site features news articles, patient stories, AML basics articles, and clinical trial updates with new content every week.

Federal Administrative Changes to Prescription Drug Costs

Mar. 23, 2023

Federal Administrative Changes to Prescription Drug Costs

Meet AML Coach, Alan Katz

Mar. 20, 2023

Meet AML Coach, Alan Katz

$What is Relapsed and Refractory AML?$

Mar. 17, 2023

What is Relapsed and Refractory AML?

Introducing the New HealthTree Coach for AML Program: Finding and Giving One-On-One Help

Mar. 13, 2023

Introducing the New HealthTree Coach for AML Program: Finding and Giving One-On-One Help

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML

Mar. 06, 2023

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML

Today is Rare Disease Day!

Feb. 28, 2023

Today is Rare Disease Day!

AML in Women vs Men

Feb. 22, 2023

AML in Women vs Men

Full Chapter Event Recording: The Caregiver's Role in AML Symptom Management

Feb. 13, 2023

Full Chapter Event Recording: The Caregiver's Role in AML Symptom Management

Transplant Recipients, Stay on Top of Your GI Screenings

Feb. 06, 2023

Transplant Recipients, Stay on Top of Your GI Screenings

Childhood AML - Learn About the Basics

Feb. 01, 2023

Childhood AML - Learn About the Basics

ASH 2022: Root Causes of Health Inequity

Jan. 30, 2023

ASH 2022: Root Causes of Health Inequity

ASH 2022: New Therapies in AML with Dr. Stein

Jan. 25, 2023

ASH 2022: New Therapies in AML with Dr. Stein

Recent Articles

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea image

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea

January 19, 2023

At the ASH 2022 meeting, Dr. Pollyea discusses his research evaluting the need for a new classification system for those receiving azacitidine and venetoclax.

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker image

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker

January 12, 2023

Dr. Becker shares with us her exciting research surrounding individualized treatments for AML patients.

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant? image

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant?

January 04, 2023

Many centers tell stem cell transplant patients to restrict their diet after transplant to prevent infection. Stats say it doesn't make much difference.

New in AML

Transplant Recipients, Stay on Top of Your GI Screenings image

Transplant Recipients, Stay on Top of Your GI Screenings

ASH 2022: Root Causes of Health Inequity image

ASH 2022: Root Causes of Health Inequity

ASH 2022: New Therapies in AML with Dr. Stein image

ASH 2022: New Therapies in AML with Dr. Stein

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea image

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker image

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant? image

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant?

Life With AML

Federal Administrative Changes to Prescription Drug Costs image

Federal Administrative Changes to Prescription Drug Costs

What is Relapsed and Refractory AML? image

What is Relapsed and Refractory AML?

Today is Rare Disease Day! image

Today is Rare Disease Day!

AML in Women vs Men image

AML in Women vs Men

Full Chapter Event Recording: The Caregiver's Role in AML Symptom Management image

Full Chapter Event Recording: The Caregiver's Role in AML Symptom Management

Grieving the Life You Thought You'd Live After an AML Diagnosis image

Grieving the Life You Thought You'd Live After an AML Diagnosis

Childhood AML

Childhood AML - Learn About the Basics image

Childhood AML - Learn About the Basics

PedAL Dare To Dream Project For Childhood AML image

PedAL Dare To Dream Project For Childhood AML

Understanding the Newly Discovered UBTF Mutation in Childhood AML image

Understanding the Newly Discovered UBTF Mutation in Childhood AML

ASH 2021: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia image

ASH 2021: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia

Targeted Therapy Using Genome Mapping for Childhood AML and Other Pediatric Cancers image

Targeted Therapy Using Genome Mapping for Childhood AML and Other Pediatric Cancers

Vyxeos Now FDA Approved for Children With Secondary AML image

Vyxeos Now FDA Approved for Children With Secondary AML

Trending Articles

Meet AML Coach, Alan Katz

Meet AML Coach, Alan Katz

What is Relapsed and Refractory AML?

What is Relapsed and Refractory AML?

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML

AML in Women vs Men

AML in Women vs Men

Introducing the New HealthTree Coach for AML Program: Finding and Giving One-On-One Help

Introducing the New HealthTree Coach for AML Program: Finding and Giving One-On-One Help

Upcoming Events

Broadening the Dialogue with Your Oncology Team about AML

Broadening the Dialogue with Your Oncology Team about AML

Mar 28 / 11:30 EDT

Open Financial Q&A for Blood Cancer Patients

Open Financial Q&A for Blood Cancer Patients

Mar 30 / 13:00 EDT

Infection Prevention for AML Patients with Sami Salvatora, PA-C

Infection Prevention for AML Patients with Sami Salvatora, PA-C

Apr 18 / 12:00 EDT

Patient Stories

articles for Patient Stories

Meet AML Coach, Alan Katz What AML Taught Me in 2022 Blood Lines – Poetry to Celebrate Blood Cancer Awareness Month

HealthTree

articles for HealthTree

Introducing the New HealthTree Coach for AML Program: Finding and Giving One-On-One Help Make a Difference This Giving Tuesday AML Round Table: What's Next if You Relapse?

Clinical Trials

articles for Clinical Trials

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML ASH 2022: Revumenib Leads to Long-Lasting Responses in KMT2Ar(MLLr) and NPM1-Mutated AML ASH 2022: Final Results of the VIALE-A Trial Assessing Venetoclax Plus Azacitidine

HealthTree Press

articles for HealthTree Press

HealthTree Foundation Launches New Journaling Feature for Acute Myeloid Leukemia Patients The HealthTree® Foundation Unveils the First and Only Clinical Trial Finder Tool Designed Specifically for Acute Myeloid Leukemia (AML) Patients HealthTree Foundation wants to ease, demystify the clinical trial process for AML patients

Healthy Recipes

articles for Healthy Recipes

No Bake, High Calorie Energy Bites

Thanks to our HealthTree Community for AML Sponsors:

Astellas Pharma

Servier

Follow Us

Apps & Programs

Cure Hub Side Effect Solutions My Journal University Coach Connect Moves

All News

All News New in AML Life With AML Patient Stories Childhood AML Clinical Trials HealthTree HealthTree Press

Events

All Events Life With AML Treatment & Testing Research Nutrition Fitness Financial Round Tables Doctor Q&A

Round Tables

Upcoming Round Tables Past Round Tables

Podcasts

Chapters

Research

Clinical Trials

Patient Resources

AML 101 Financial Resources Find a Specialist

HealthTree Info

About HealthTree HealthTree in The News Annual Reports

Need Help?

Contact Us 1-800-930-5159

Legal Info

Terms of Use Privacy Policy

HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

Copyright © 2022 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811